FAMVIR Film-coated tablets (2018)
Βιβλιογραφική αναφορά
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Περιεχόμενα
Name of the medicinal product
Famvir 125 mg film-coated tablets. Famciclovir 125 mg film-coated tablets.
Qualitative and quantitative composition
Each film-coated tablet contains 125 mg of famciclovir. Excipient with known effects: Each film-coated tablet contains 26.85 mg of lactose, anhydrous. For the full list of excipients, see section 6.1. ...
Pharmaceutical form
Film-coated tablet. White, round film-coated tablet, biconvex, bevelled edges, debossed with FV on one side and 125 on the reverse side.
Therapeutic indications
Varicella zoster virus (VZV) infections – herpes zoster Famvir is indicated for: the treatment of herpes zoster and ophthalmic zoster in immunocompetent adults (see section 4.4) the treatment of herpes ...
Posology and method of administration
Herpes zoster and ophthalmic zoster in immunocompetent adults 500 mg three times daily for seven days. Treatment should be initiated as soon as possible after a diagnosis of herpes zoster or ophthalmic ...
Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Hypersensitivity to penciclovir.
Special warnings and precautions for use
Use in patients with renal impairment In patients with impaired renal function dose adjustment is necessary (see sections 4.2 and 4.9). Use in patients with hepatic impairment Famciclovir has not been ...
Interaction with other medicinal products and other forms of interaction
Effects of other medicinal products on famciclovir No clinically significant interactions have been identified. Concurrent use of probenecid may result in increased plasma concentrations of penciclovir, ...
Fertility, pregnancy and lactation
Women of child-bearing potential There are no data supporting any special recommendations in women of child-bearing potential. Patients with genital herpes should be advised to avoid intercourse when symptoms ...
Effects on ability to drive and use machines
No studies on the effects on the ability to drive and use machines have been performed. However, patients who experience dizziness, somnolence, confusion or other central nervous system disturbances while ...
Undesirable effects
Headache and nausea have been reported in clinical studies. These were generally mild or moderate in nature and occurred at a similar incidence in patients receiving placebo treatment. All other adverse ...
Overdose
Overdose experience with famciclovir is limited. In the event of an overdose supportive and symptomatic therapy should be given as appropriate. Acute renal failure has been reported rarely in patients ...
Pharmacodynamic properties
Pharmacotherapeutic group: Nucleosides and nucleotides excluding reverse transcriptase inhibitor ATC code: J05AB09 Mechanism of action Famciclovir is the oral prodrug of penciclovir. Famciclovir is rapidly ...
Pharmacokinetic properties
General characteristics Absorption Famciclovir is the oral prodrug of the antivirally active compound penciclovir. Following oral administration, famciclovir is rapidly and extensively absorbed and converted ...
Preclinical safety data
General toxicity Studies on safety pharmacology and repeated dose toxicity reveal no special hazard for humans. Genotoxicity Famciclovir was not found to be genotoxic in a comprehensive battery of in vivo ...
List of excipients
Tablet core: Lactose, anhydrous Sodium starch glycolate (Type A) Hydroxypropyl cellulose Magnesium stearate Tablet coat: Hypromellose Titanium dioxide (E171) Macrogol 4000 Macrogol 6000
Incompatibilities
Not applicable.
Shelf life
Shelf life: 3 years.
Special precautions for storage
Do not store above 25°C. Store in the original package in order to protect from moisture.
Nature and contents of container
Famvir is supplied in PVC/PCTFE/Aluminium blister packs containing 10 tablets.
Special precautions for disposal and other handling
Any unused product or waste material should be disposed of in accordance with local requirements.
Marketing authorization holder
Novartis Pharmaceuticals UK Ltd, Frimley Business Park, Frimley, Camberley, Surrey, GU16 7SR, United Kingdom
Marketing authorization number(s)
PL 00101/0625
Date of first authorization / renewal of the authorization
21 April 1995/08 July 2011
Date of revision of the text
15 October 2018
Πηγαίο έγγραφο
Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:
